Figure 3.

Effect of resolvin D1 (60 ng/animal by intraperitoneal route) on STZ-induced type 2 diabetes mellitus. Resolvin D1 not only abrogated STZ-induced diabetes but also suppressed STZ-induced increase in plasma IL-6 and TNF-α levels and restored plasma LXA4 and BDNF to normal (these data are taken from ref. [14]). (A) ^a p ≤ 0.001 compared to untreated control; ^b p ≤ 0.01 compared to streptozotocin + nicotinamide (STZ + NA) group. (B) ^a p ≤ 0.01 compared to STZ + NA, and ^b p ≤ 0.01 compared to untreated control. TNF-α studies, ^a p ≤ 0.01 compared to control, and ^b p ≤ 0.05 compared to STZ + NA. IL-6 studies; ^a p ≤ 0.01 and ^c p ≤ 0.01 compared to control. ^b p ≤ 0.01 compared to STZ + NA group. All values are expressed as mean ± SEM.